Literature DB >> 17090194

Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases.

Nicole Nicosia Esposito1, Deepak Mohan, Adam Brufsky, Yan Lin, Malathy Kapali, David J Dabbs.   

Abstract

CONTEXT: Phyllodes tumors (PTs) of the breast are biphasic neoplasms composed of epithelium and a spindle-cell stroma. Currently, PTs are classified as benign, borderline, or malignant based on histopathologic features. However, histologic classification does not always predict outcome. Objective.-To determine the prognostic value of a variety of clinicopathologic features and immunoreactivities in PTs.
DESIGN: Sixteen benign, 8 borderline, and 6 malignant PTs with follow-up were examined for reactivity across a panel of immunohistochemical stains, including c-Kit, endothelin 1, p16, p21, p53, and Ki-67. Clinicopathologic features, including stromal cellularity, mitotic rate, and margin status, were also assessed. Tumor variables were compared among tumor subgroups and between tumors that did and did not recur.
RESULTS: Of the 30 PTs, 4 recurred (1 benign, 2 borderline, 1 malignant). One patient with a malignant tumor died of metastatic disease 34 months after initial diagnosis. The overall positive rate of c-Kit immunoreactivity was 13% in benign, 63% in borderline, and 67% in malignant PTs. Endothelin 1 epithelial cytoplasmic staining was seen in 100% of benign, 50% of borderline, and 17% of malignant PTs. Additionally, p16, p21, p53, and Ki-67 were differentially expressed among benign, borderline, and malignant tumors. Positive surgical resection margins was the only variable that significantly predicted recurrent disease (P = .02).
CONCLUSIONS: Stromal c-Kit positivity and epithelial endothelin 1 negativity are more often associated with malignant PTs; however, only positive margin status is significantly associated with tumor behavior.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17090194     DOI: 10.5858/2006-130-1516-PTACAI

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  16 in total

1.  In phyllodes tumors of the breast expression of SPARC (osteonectin/BM40) mRNA by in situ hybridization correlates with protein expression by immunohistochemistry and is associated with tumor progression.

Authors:  Nah Ihm Kim; Ga-Eon Kim; Ji Shin Lee; Min Ho Park
Journal:  Virchows Arch       Date:  2016-12-01       Impact factor: 4.064

Review 2.  Width of margins in phyllodes tumors of the breast: the controversy drags on?-a systematic review and meta-analysis.

Authors:  Arnaud Toussaint; Romain Piaget-Rossel; Coraline Stormacq; Patrice Mathevet; Karine Lepigeon; Patrick Taffé
Journal:  Breast Cancer Res Treat       Date:  2020-09-15       Impact factor: 4.872

3.  Molecular pathogenesis of progression and recurrence in breast phyllodes tumors.

Authors:  Ana Richelia Jara-Lazaro; Puay Hoon Tan
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

4.  Borderline and malignant phyllodes tumors display similar promoter methylation profiles.

Authors:  Jo-Heon Kim; Yoo Duk Choi; Ji Shin Lee; Jae Hyuk Lee; Jong Hee Nam; Chan Choi; Min Ho Park; Jung Han Yoon
Journal:  Virchows Arch       Date:  2009-11-19       Impact factor: 4.064

5.  Suppression of breast cancer metastasis through the inhibition of VEGF-mediated tumor angiogenesis.

Authors:  Jun Zhang; Andrew Lu; Derrick Beech; Binghua Jiang; Yi Lu
Journal:  Cancer Ther       Date:  2007

6.  CD117 expression in breast phyllodes tumors correlates with adverse pathologic parameters and reduced survival.

Authors:  Wai Jin Tan; Aye Aye Thike; Sie Yong Tan; Gary M-K Tse; Min-Han Tan; Boon Huat Bay; Puay Hoon Tan
Journal:  Mod Pathol       Date:  2014-09-12       Impact factor: 7.842

7.  A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway.

Authors:  Ashley Cimino-Mathews; Jessica L Hicks; Rajni Sharma; Russell Vang; Peter B Illei; Angelo De Marzo; Leisha A Emens; Pedram Argani
Journal:  Hum Pathol       Date:  2013-07-31       Impact factor: 3.466

8.  Phyllodes tumor of the breast: a clinic-pathologic study of 77 cases in a Hispanic cohort.

Authors:  Carlos Andres Ossa; Fernando Herazo; Monica Gil; Carolina Echeverri; Gonzalo Ángel; Mauricio Borrero; Jorge Madrid; Ricardo Jaramillo
Journal:  Colomb Med (Cali)       Date:  2015-09-30

Review 9.  Phyllodes tumours of the breast: a consensus review.

Authors:  Benjamin Y Tan; Geza Acs; Sophia K Apple; Sunil Badve; Ira J Bleiweiss; Edi Brogi; José P Calvo; David J Dabbs; Ian O Ellis; Vincenzo Eusebi; Gelareh Farshid; Stephen B Fox; Shu Ichihara; Sunil R Lakhani; Emad A Rakha; Jorge S Reis-Filho; Andrea L Richardson; Aysegul Sahin; Fernando C Schmitt; Stuart J Schnitt; Kalliopi P Siziopikou; Fernando A Soares; Gary M Tse; Anne Vincent-Salomon; Puay Hoon Tan
Journal:  Histopathology       Date:  2016-01       Impact factor: 5.087

10.  Phyllodes tumor of the breast: role of Axl and ST6GalNAcII in the development of mammary phyllodes tumors.

Authors:  Dongliang Ren; Yanyan Li; Yanxin Gong; Jingchao Xu; Xiaolong Miao; Xiangnan Li; Chen Liu; Li Jia; Yongfu Zhao
Journal:  Tumour Biol       Date:  2014-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.